Generalized Myasthenia Gravis (gMG) Treatment | IMAAVY™ (nipocalimab-aahu)

For patients 12 years of age and older living with anti-AChR or anti-MuSK antibody-positive generalized myasthenia gravis (gMG)

How does IMAAVY work?

IMAAVY is designed to reduce

harmful IgG antibodies

, including anti-AChR and anti-MuSK, by binding and

blocking FcRn receptors

. These antibodies can cause

gMG

symptoms.

How IMAAVY worksLearn how IMAAVY works

What could IMAAVY
do for me?

Significant improvement
in daily function* and muscle
weakness^†

Disease control that lasts,
as measured by improvement in daily function* in a 24-week

clinical study

In the study, patients were given IMAAVY + their current gMG treatment or placebo + their current gMG treatment. Current therapies included acetylcholinesterase inhibitors, steroids, or non-steroidal immunosuppressive therapies, taken together or separately.

*Measured using the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, which assesses the impact of gMG on 8 daily-function items that are typically affected in gMG. The average reduction from baseline to Weeks 22, 23, and 24 in MG-ADL total score was 4.7 for people taking IMAAVY + current gMG treatment and 3.3 for people taking placebo + current gMG treatment.

^†Measured using the Quantitative Myasthenia Gravis (QMG) scale, which assesses muscle weakness based on 13 items. The average reduction from baseline to Weeks 22 and 24 in QMG score was 4.9 for people taking IMAAVY + current gMG treatment and 2.1 for people taking placebo + current gMG treatment.

See study results